Highlights Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 14:45:49 05/03/2026 GMT			5-day change	1st Jan Change
144.50 ^USD	-2.51%		+0.75%	+20.76%

01:20pm	The Year the Easy Narrative Broke
06:03am	South Africa seeks local production of Gilead's HIV prevention drug	RE

Highlights

03-02	United Therapeutics' drug slows progression of rare lung condition in late-stage study	RE
02-25	Arcus Biosciences Provides Pipeline Update on Its Clinical-Stage Investigational Molecules and Discovery Programs	CI
02-25	Gilead Sciences, Inc. Announces the Presentation of New Phase 3 ARTISTRY-1 and ARTISTRY-2 Trial Data At CROI 2026	CI
02-25	Gilead's experimental HIV treatment shows low discontinuation rates in studies	RE
02-24	Gilead Sciences Acquiring Arcellx to Consolidate Anito-Cel Ownership, UBS Securities Says	MT
02-23	Health Care Up on Defensive Bias, Even as Novo Nordisk Falls -- Health Care Roundup	DJ
02-23	Dow Logs Worst Day in Nearly 5 Weeks Amid Renewed Tariffs Uncertainty; Tech Stocks Fall	MT
02-23	Sector Update: Health Care Stocks Higher Late Afternoon	MT
02-23	Equities, Treasury Yields Fall Intraday as Markets Weigh New Trump Tariffs	MT
02-23	Top Midday Gainers	MT
02-23	Gilead Sciences, Inc. entered into an agreement to acquire the remaining 88.50% stake in Arcellx, Inc. from New Enterprise Associates, Inc., Sr One Capital Fund I Aggregator, LP, fund managed by SR One Capital Management, LP, and others for approximately $6.6 billion.	CI
02-23	Top Midday Stories: Novo Obesity Drug Doesn't Meet Primary Endpoint, Stock Falls; Gilead to Acquire Arcellx for $7.8 Billion	MT
02-23	Arcellx Shares Rise After $7.8 Billion Acquisition Deal With Gilead	MT
02-23	Global markets live: Nvidia, Gilead, Goldman Sachs, Delta Air Lines, Novo Nordisk…
02-23	Gilead Sciences to Acquire Arcellx in $7.8 Billion Deal	MT
02-23	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday Amid Renewed Trade Doubts	MT
02-23	Stocks Down Pre-Bell as Trump Raises Global Tariffs Following Supreme Court Ruling	MT
02-23	Top Premarket Gainers	MT
02-23	Gilead Sciences to Buy Arcellx in Deal Valuing Biotech at $7.8 Billion -- Update	DJ
02-23	Gilead to Acquire Arcellx for $7.8 Billion to Expand CAR T-Cell Cancer Therapies	MT
02-23	Gilead Sciences to Buy Arcellx in Deal Valuing Biotech at $7.8 Billion	DJ
02-23	Gilead to Acquire Arcellx in $7.8 Billion Deal	MT
02-23	Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion	RE
02-23	Gilead Sciences to acquire Arcellx to maximize long-term potential of Anito-cel	RE
02-23	Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Filters

Headlines

Time To Grow PFL Fanbase, Revenue: CEO John Martin

July 11, 2025 at 09:09 am